Revenue Update on AVEO Pharmaceuticals(NASDAQ:AVEO)

AVEO Pharmaceuticals(NASDAQ:AVEO) announced the earnings results for Fiscal Year 2016 and Q4. The results came in during After-Market on Mar 22, 2017. Based on the corporate Earnings and Guidance, many Investment Banking firms balance their portfolio to Sell and Buy Stocks based on their strategy of investing in stocks.Company reported revenue of $127.000K. Analysts estimated a revenue of $100.000K. The revenues were 27% above the estimates. Earnings per share were $-0.07. The reported EPS was above estimates by 36.36%. Analysts had estimated an EPS of $-0.11.

AVEO Pharmaceuticals (AVEO) shares turned negative on Fridays trading session with the shares closing down -0.0446 points or -6.24% at a volume of 7,65,158. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $0.71. The peak price level was also seen at $0.71 while the days lowest was $0.6131. Finally the shares closed at $0.67. The 52-week high of the shares is $1.15 while the 52-week low is $0.54. According to the latest information available, the market cap of the company is $51 M.

Several Insider Transactions has been reported to the SEC. On Jan 20, 2015, Matthew D Dallas (VP, Finance) sold 3,075 shares at $0.82 per share price.Also, On Jan 8, 2015, Jeno Gyuris (SVP, Chief Scientific Officer) sold 4,484 shares at $0.80 per share price.On Jan 8, 2015, Joseph Vittiglio (SVP, General Counsel) sold 4,484 shares at $0.80 per share price, according to the Form-4 filing with the securities and exchange commission.

AVEO Pharmaceuticals Inc. (AVEO) is a biopharmaceutical company. The Company’s platform has delivered insights into cancer and related disease. The Company’s Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company’s product candidates include AV203 Ficlatuzumab Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Add Comment